Reuters logo
BRIEF-Spark Therapeutics announces U.S. Orphan drug designation amendment for lead investigational Gene Therapy
January 9, 2017 / 1:05 PM / 8 months ago

BRIEF-Spark Therapeutics announces U.S. Orphan drug designation amendment for lead investigational Gene Therapy

Jan 9 (Reuters) - Spark Therapeutics Inc :

* Spark Therapeutics announces U.S. Orphan drug designation amendment and study updates for lead investigational Gene Therapy

* FDA grants request to amend Orphan Drug Designation for voretigene neparvovec

* Initiated rolling submission of biologics license application (BLA), which is expected to be completed in early 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below